IGF2BP1 and liver cancer: For instance, PRMT3 promotes liver cancer growth by methylating LDHA, confers oxaliplatin resistance by methylating IGF2BP1, and mediates immunotherapy resistance by methylating HSP60.[13, 32, 33] In this study, PRMT3's methylation of YBX1 also occurred in the cytoplasm.